JP2011522874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522874A5 JP2011522874A5 JP2011513069A JP2011513069A JP2011522874A5 JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5 JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- virus strain
- vaccine
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712431 Influenza A virus Species 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 206010064097 avian influenza Diseases 0.000 claims description 46
- 206010069767 H1N1 influenza Diseases 0.000 claims description 41
- 201000010740 swine influenza Diseases 0.000 claims description 41
- 241000713196 Influenza B virus Species 0.000 claims description 39
- 229960003971 influenza vaccine Drugs 0.000 claims description 38
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000007764 o/w emulsion Substances 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000000185 hemagglutinin Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 108010064983 Ovomucin Proteins 0.000 claims description 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 2
- 239000005388 borosilicate glass Substances 0.000 claims description 2
- 230000035931 haemagglutination Effects 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 229940117432 influenza b virus antigen Drugs 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13191808P | 2008-06-12 | 2008-06-12 | |
| US61/131,918 | 2008-06-12 | ||
| GB0905570.8 | 2009-03-31 | ||
| GBGB0905570.8A GB0905570D0 (en) | 2009-03-31 | 2009-03-31 | Combined vaccines |
| PCT/IB2009/006038 WO2009150532A1 (en) | 2008-06-12 | 2009-06-12 | Combined influenza vaccines for seasonal and pandemic protection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522874A JP2011522874A (ja) | 2011-08-04 |
| JP2011522874A5 true JP2011522874A5 (enExample) | 2012-07-19 |
Family
ID=40672059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513069A Pending JP2011522874A (ja) | 2008-06-12 | 2009-06-12 | 季節性および汎流行性の防御のための混合インフルエンザワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110200635A1 (enExample) |
| EP (1) | EP2303321A1 (enExample) |
| JP (1) | JP2011522874A (enExample) |
| KR (1) | KR20110019417A (enExample) |
| CN (1) | CN102245203A (enExample) |
| AU (1) | AU2009259006A1 (enExample) |
| CA (1) | CA2727322A1 (enExample) |
| GB (1) | GB0905570D0 (enExample) |
| WO (1) | WO2009150532A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2358386T3 (en) * | 2008-11-28 | 2017-02-13 | Statens Seruminstitut | Optimized flu vaccine |
| SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| USH2284H1 (en) * | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| US20120219584A1 (en) * | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| AU2011217903B2 (en) | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| JP5884100B2 (ja) * | 2011-08-31 | 2016-03-15 | 公益財団法人東京都医学総合研究所 | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス |
| WO2013043729A1 (en) | 2011-09-20 | 2013-03-28 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| EP2822585B1 (en) * | 2012-03-06 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Improved vaccination against influenza |
| HK1215546A1 (zh) | 2012-12-17 | 2016-09-02 | Eurocine Vaccines Ab | 鼻内接种疫苗给药方案 |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| CN105636609A (zh) * | 2013-10-25 | 2016-06-01 | 白血球保健股份有限公司 | 一种新颖的生产稳定疫苗的方法 |
| EP3233117A4 (en) * | 2014-12-19 | 2018-05-16 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| WO2016104584A1 (ja) * | 2014-12-25 | 2016-06-30 | 第一三共株式会社 | 皮内投与インフルエンザワクチン組成物 |
| WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
| US11266734B2 (en) | 2016-06-15 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CN107151659B (zh) * | 2017-03-01 | 2021-04-02 | 苏州系统医学研究所 | 一种流感病毒株及其应用 |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| AU2018357917B2 (en) | 2017-10-30 | 2024-08-01 | Takeda Pharmaceutical Company Limited | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| WO2019143955A1 (en) * | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
| WO2019246363A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1645283A1 (en) * | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
| AR052625A1 (es) * | 2005-03-23 | 2007-03-21 | Glaxosmithkline Biolog Sa | Nueva composicion |
| JP2009514850A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
| WO2007052060A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines extemporaneously adsorbed to aluminium adjuvants |
| WO2007144772A2 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
| ES2536401T3 (es) * | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| AU2007330494B2 (en) * | 2006-12-06 | 2014-03-13 | Seqirus UK Limited | Vaccines including antigen from four strains of influenza virus |
| JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
| TWI403518B (zh) * | 2007-01-23 | 2013-08-01 | Academia Sinica | 一種流感疫苗及其使用方法 |
| GB0810305D0 (en) * | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| WO2009071633A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
| ES2535101T3 (es) * | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
-
2009
- 2009-03-31 GB GBGB0905570.8A patent/GB0905570D0/en not_active Ceased
- 2009-06-12 US US12/997,577 patent/US20110200635A1/en not_active Abandoned
- 2009-06-12 AU AU2009259006A patent/AU2009259006A1/en not_active Abandoned
- 2009-06-12 CN CN2009801230987A patent/CN102245203A/zh active Pending
- 2009-06-12 WO PCT/IB2009/006038 patent/WO2009150532A1/en not_active Ceased
- 2009-06-12 KR KR1020117000394A patent/KR20110019417A/ko not_active Ceased
- 2009-06-12 JP JP2011513069A patent/JP2011522874A/ja active Pending
- 2009-06-12 EP EP09762060A patent/EP2303321A1/en not_active Withdrawn
- 2009-06-12 CA CA2727322A patent/CA2727322A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,852 patent/US20140363468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522874A5 (enExample) | ||
| Becker et al. | Influenza vaccines: successes and continuing challenges | |
| Vasou et al. | Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses | |
| Cappellano et al. | Nano-microparticle platforms in developing next-generation vaccines | |
| Kumar et al. | Novel platforms for the development of a universal influenza vaccine | |
| Vemula et al. | Vaccine approaches conferring cross-protection against influenza viruses | |
| Cargnin Faccin et al. | Pandemic preparedness through vaccine development for avian influenza viruses | |
| Sekiya et al. | Selecting and using the appropriate influenza vaccine for each individual | |
| Zhang et al. | Universal influenza vaccines, a dream to be realized soon | |
| Isakova-Sivak et al. | Influenza vaccine: Progress in a vaccine that elicits a broad immune response | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| Li et al. | Adjuvantation of influenza vaccines to induce cross-protective immunity | |
| Clegg et al. | Clinical vaccine development for H5N1 influenza | |
| Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
| ES2469568T3 (es) | Vacuna contra la gripe | |
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| Hatz et al. | A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects | |
| Rudenko et al. | Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus | |
| Hsiung et al. | Vaccine strategies against RNA viruses: current advances and future directions | |
| Esposito et al. | Preventing influenza in younger children | |
| Chu et al. | Respiratory viruses and virus-like particle vaccine development: how far have we advanced? | |
| Deans et al. | Influenza vaccines provide diminished protection but are cost‐saving in older adults | |
| Tosh et al. | Emerging vaccines for influenza | |
| EP2822585B1 (en) | Improved vaccination against influenza | |
| Mokalla et al. | Influenza vaccines: current status, adjuvant strategies, and efficacy |